Literature DB >> 1233266

Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

W Zilly, D D Breimer, E Richter.   

Abstract

Five healthy volunteers took 1.2 g rifampicin daily for 8 days, and before and afterwards each received hexobarbital (7.32 mg/kg) and tolbutamide (20 mg/kg) by i.v. infusion on two consecutive days. The plasma concentrations of the two drugs were determined during and after infusion. The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment. It was calculated that the metabolic clearance of hexobarbital had increased about three-fold and that of tolbutamide more than two-fold. Significant changes in the distribution kinetics of the two drugs were not observed. The results suggest that rifampicin is capable of inducing drug metabolism in man, which leads to an increased rate of elimination of drugs that undergo biotransformation in the liver.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233266     DOI: 10.1007/bf00614021

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  [The possibility of colorimetric determination of N-(4-methyl-benzolsulfonyl)-N'-butyl urea in blood].

Authors:  H SPINGLER
Journal:  Klin Wochenschr       Date:  1957-05-15

2.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

Review 3.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

4.  Serum concentration of rifampin after oral administration.

Authors:  S Virtanen; E Tala
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

5.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  The stimulant effect of drugs on indocyanine green clearance by the liver.

Authors:  V Melikian; J D Eddy; A Paton
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

7.  Rifampicin desacetylation in the human organism.

Authors:  N Maggi; S Furesz; R Pallanza; G Pelizza
Journal:  Arzneimittelforschung       Date:  1969-04

8.  [Binding of sulfonamides to protein. 6. Determination of protein binding of sulfonamides by means of ultracentrifuge and gel filtration].

Authors:  W Scholtan
Journal:  Arzneimittelforschung       Date:  1965-12

9.  Pharmocokinetics of hexobarbital in man after intravenous infusion.

Authors:  D D Breimer; C Honhoff; W Zilly; E Richter; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1975-02

10.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  34 in total

1.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 4.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.

Authors:  E A Sotaniemi; R O Pelkonen; M Puukka
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

6.  Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

Authors:  H H Zhou; L B Anthony; A J Wood; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

9.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 10.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.